Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

The introduction cites multiple prior studies establishing PARP inhibitor efficacy in mCRPC with HRR alterations, the synergy between PARP and androgen receptor inhibition, and the unmet need in mCSPC. It acknowledges limitations of prior work, such as resistance to PARP monotherapy and the shift of androgen receptor pathway inhibitors to earlier disease settings. The hypothesis that PARP inhibition at first-line androgen deprivation could be effective is logically derived from this evidence.

Randomization was performed using permuted block randomization via an interactive web system, with stratification by HRR gene, prior docetaxel, and metastases volume. The trial is double-blind, with blinding maintained after progression for overall survival follow-up. A power analysis is provided for the primary endpoint and key subgroups. Inclusion/exclusion criteria are detailed in the methods and protocol. The hierarchical graphical testing approach controls the family-wise type I error rate. For a human RCT, replicate_distinction, controls (wet-lab), and independent_replication are not applicable; outlier_handling is mapped to the analysis population (ITT) and missing data approach (data-as-observed), which is reported but not fully pre-specified for missing data handling.

Sex is reported (all male, as expected for prostate cancer). Age is reported with median, range, and by group. Demographics are comprehensively reported including race, region, ECOG performance status, Gleason score, metastatic stage, and PSA levels. A justification for a single-sex study is not required as this is a disease-specific trial in prostate cancer. Species/strain/housing are not applicable to this human trial.

The methods state that the protocol was approved by the review board at each participating institution and health authorities in every participating country. The trial was conducted in accordance with ICH-GCP and the Declaration of Helsinki. All patients provided written informed consent. A named ethics body is not explicitly listed in the paper text, but the statement of approval by 'the review board at each participating institution' is standard for a multinational trial and is considered adequate. The trial is registered at ClinicalTrials.gov (NCT04497844).

The investigational products are clearly identified: niraparib (200 mg), abiraterone acetate (1000 mg), and prednisone (5 mg) with dosing regimen. The central testing assays are named with vendors (Foundation Medicine, Invitae). Statistical software (Medidata, East, SAS) with versions is reported. Antibodies, cell lines, mycoplasma testing, and organisms are not applicable for this human drug trial. Reagents_identified is scored against the investigational products and is adequate.

The primary analysis uses stratified log-rank tests and Cox proportional hazards models, which are named. Exact p-values (e.g., P < 0.0001, P = 0.0001) and 95% confidence intervals are reported for all key endpoints. Effect sizes (hazard ratios) are provided with CIs. Statistical software is identified. Data presentation includes Kaplan-Meier curves with number at risk, forest plots, and baseline tables with per-group n. For a large clinical trial with time-to-event endpoints, assumptions_verified is adequate as the Cox model's proportional hazards assumption is standard and not explicitly tested but is a design consideration. Mathematical_plausibility is not applicable for time-to-event data.

The data availability statement names the YODA project as the access route for de-identified participant-level data, which is adequate for a clinical trial with patient-level data. Repository deposit and accession numbers are not applicable for identifiable patient-level data, but the trial may have generated non-identifiable data (e.g., sequencing data) that could be deposited; none are reported. Code sharing is not reported; the statistical analysis used standard software (SAS), but custom code for analyses is not mentioned. The statement is adequate for the primary data type, but the lack of code sharing and potential for depositable non-identifiable data leads to a 'warn' status.

Methods are comprehensive, including trial design, participants, procedures, endpoints, and statistical analysis. The trial is registered at ClinicalTrials.gov with identifier NCT04497844. A reporting summary is linked. Limitations are explicitly discussed in the Discussion section, including the small size of individual gene subgroups, lack of formal crossover, and the immature overall survival data. Conclusions are proportional, noting the benefit in BRCA subgroups and the need for further follow-up. Funding (Johnson & Johnson) and conflicts of interest are disclosed in detail.